AstraZeneca amends collaboration with Ironwood for Linzess in China

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Related Links:

Conclusions: FAPDs and FDDs are common in adolescents in Curacao. Dizziness is associated with the presence of a FAPD or FDD.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Gastroenterology Source Type: research
AbstractPurpose of ReviewTo evaluate the impact of the implementation of the Rome IV criteria on pediatric gastrointestinal practice.Recent FindingsIn 2016, the Rome IV criteria were published, providing an update of symptom-based criteria to diagnose children with functional gastrointestinal disorders (FGIDs).SummaryFor neonates and toddlers, Wessel ’s criteria for diagnosing infant colic were abandoned, and a differentiation was made between toilet-trained and non-toilet-trained children in the diagnosis of functional constipation. For children and adolescents, two new disorders (functional nausea and functional vo...
Source: Current Gastroenterology Reports - Category: Gastroenterology Source Type: research
Treatment options for irritable bowel syndrome with constipation (IBS-C) are limited —new prokinetic drugs are needed. We evaluated the efficacy and safety of minesapride (DSP-6952), a partial agonist with high affinity for 5-HT4 receptors, in patients with IBS-C in Japan.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Lower urinary tract storage symptoms are common women ’s health conditions that increase with advancing age. However, symptoms are also common among young women. Understanding the experience of symptoms in young women may help to decrease symptom progression across the life span. The current study was a quantitative Web-based study of female undergra duates. The most commonly reported symptoms were urinary frequency, urgency, and urinary incontinence. Factors that were significantly associated with lower urinary tract storage symptoms included constipation/irritable bowel syndrome, sexual activity, and delayed and/or...
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Original Research Source Type: research
Goals: We aimed to study (1) if the breath methane level on glucose breath testing (GBT) was associated with constipation severity and (2) compare methane levels between patients with constipation and diarrhea. Background: The breath methane level has been associated with constipation and its severity. However, a few recent studies have questioned these associations. Study: Patients presenting consecutively to a tertiary care gastroenterology motility laboratory for GBT were included. GBT was performed using 75-g glucose load following a standard, institutional protocol. Constipation and irritable bowel syndrome (I...
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: Alimentary Tract: Original Articles Source Type: research
CONCLUSIONS: The prevalence of irritable bowel syndrome in adolescents was high, with bullying, female gender, age 14-16 years, constipation and diarrhea, and dietary consumption of soft drinks, coffee, and tea as risk factors. A significant association with intestinal inflammation was found. PMID: 32156535 [PubMed - as supplied by publisher]
Source: Jornal de Pediatria - Category: Pediatrics Authors: Tags: J Pediatr (Rio J) Source Type: research
AbstractMinesapride (drug code: DSP ‐6952) is a potential gastrointestinal prokinetic agent with high selectivity for 5‐hydroxytryptamine 4 (5‐HT4) receptor that acts as a partial agonist. Although 5 ‐HT4 receptor agonists are expected to show efficacy in patients with irritable bowel syndrome with constipation, only tegaserod is available for female patients, with limitations, in the United States. Previously, another 5 ‐HT4 receptor agonist, cisapride, was widely used for the treatment of upper gastrointestinal diseases, but was withdrawn from the market because of arrhythmia with QT prolongation. Chemically, b...
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Tags: Original Manuscript Source Type: research
Date: March 23, 2020 Issue #:  1594Summary:  Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Alosetron amitiza Amitriptyline anaspaz Antibacterials Antidepressants bentyl Celexa Cholestyramine Citalopram Colesevelam Colestid Colestipol Constipation Desipramine Diarrhea dicyclomine eluxadoline fluoxetine Hyosc Source Type: research
This article presents the psychometric evaluation of the DIBSS-C abdominal score.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Irritable bowel syndrome (IBS) is one of the most common functional bowel disorder worldwide (Clin Gastroenterol Hepatol 2012;10:712-721). The diagnosis is based on a patient reporting a specific combination of symptoms, as defined by the Rome criteria: abdominal pain, which is related to defecation, associated with a change in stool frequency or form (Gastroenterology 2016;150:1393-1407). IBS is further sub-grouped dependent on predominant stool form, be that diarrhea (IBS-D), constipation (IBS-C), or mixed stool pattern (IBS-M).
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
More News: AstraZeneca | China Health | Constipation | Hong Kong Health | Irritable Bowel Syndrome | Macau Health | Pharmaceuticals